fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.

Incobotulinumtoxina

All strengths: Limited Use, Reason for Use code 130, 412, 421 required; same patient cost rules

Shared coverage and patient cost rules
StatusLimited Use, Reason for Use code 130, 412, 421 required
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.

Xeomin · DIN 02371081 · 50 LD50 Units · Pd for injection-vial

Limited Use, Reason for Use code 130, 412, 421 requiredMarketed · checked October 5, 2026
Write on scriptone applicable Reason for Use code, 130 or 412 or 421 (criteria below)
Ontario Limited Use criteria, code 130, 412, 421
Reason for Use code 130 To reduce the subjective symptoms and objective signs of cervical dystonia (spasmodic torticollis) in adults. Coverage limit: LU Authorization Period: 1 year Reason for Use code 412 For the management of focal spasticity, due to stroke or spinal cord injury in adults. Coverage limit: LU Authorization Period: 1 year Reason for Use code 421 For the treatment of blepharospasm associated with dystonia, including benign essential blepharospasm or VII nerve disorders in adults. Coverage limit: LU Authorization Period: 1 year Coverage limit: Xeomin should be administered personally by a neurologist or a physician with equivalent post-graduate training and experience with neuromuscular disorders.
No interchangeable product listed in the Ontario extract
Xeomin · DIN 02371081 Manufacturer: Merz Pharmaceutical Gmbh; listing date 2013-10-31 Health Canada: Marketed since 2021-07-16 · brand XEOMIN · ATC M03AX01 BOTULINUM TOXIN · form Powder for solution · route Intraglandular, Intramuscular · ingredients INCOBOTULINUMTOXINA 50 UNIT/VIAL · company Merz pharmaceuticals gmbh · schedule Prescription, Schedule d
Re-check Health Canada status and shortages (live) · Health Canada product record

Xeomin: Formulary list price $169.46 per unit (the source does not state the unit; exact figure $169.4550). What the ministry pays, not the patient.

Ministry pays: $169.4550 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02371081)

Source record
DIN 02371081: Xeomin Raw flags: sec12=Y, sec3=Y Item: 920000684; group id 924; item number 2200; lccId 00427; manufacturer id MEZ Source form: Pd for Inj-Vial Pk; strength: 50 LD50 Units Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $169.4550; ministry $169.4550 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02371081 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85628
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02371081
Shortage record checked October 6, 2026

Xeomin · DIN 02324032 · 100 LD50 Units · Pd for injection-vial

Limited Use, Reason for Use code 130, 412, 421 requiredMarketed · checked October 5, 2026
Write on scriptone applicable Reason for Use code, 130 or 412 or 421 (criteria below)
Ontario Limited Use criteria, code 130, 412, 421
Reason for Use code 130 To reduce the subjective symptoms and objective signs of cervical dystonia (spasmodic torticollis) in adults. Coverage limit: LU Authorization Period: 1 year Reason for Use code 412 For the management of focal spasticity, due to stroke or spinal cord injury in adults. Coverage limit: LU Authorization Period: 1 year Reason for Use code 421 For the treatment of blepharospasm associated with dystonia, including benign essential blepharospasm or VII nerve disorders in adults. Coverage limit: LU Authorization Period: 1 year Coverage limit: Xeomin should be administered personally by a neurologist or a physician with equivalent post-graduate training and experience with neuromuscular disorders.
No interchangeable product listed in the Ontario extract
Xeomin · DIN 02324032 Manufacturer: Merz Pharmaceutical Gmbh; listing date 2011-05-19 Health Canada: Marketed since 2021-09-23 · brand XEOMIN · ATC M03AX01 BOTULINUM TOXIN · form Powder for solution · route Intraglandular, Intramuscular · ingredients INCOBOTULINUMTOXINA 100 UNIT/VIAL · company Merz pharmaceuticals gmbh · schedule Prescription, Schedule d
Re-check Health Canada status and shortages (live) · Health Canada product record

Xeomin: Formulary list price $338.91 per unit (the source does not state the unit; exact figure $338.9100). What the ministry pays, not the patient.

Ministry pays: $338.9100 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02324032)

Source record
DIN 02324032: Xeomin Raw flags: sec12=Y, sec3=Y Item: 920000624; group id 924; item number 2201; lccId 00427; manufacturer id MEZ Source form: Pd for Inj-Vial Pk; strength: 100 LD50 Units Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $338.9100; ministry $338.9100 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02324032 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80952
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02324032
Shortage record checked October 6, 2026

Xeomin · DIN 02556227 · 200 Units/Vial · Pd for injection-vial (Preservative-Free)

Limited Use, Reason for Use code 130, 412, 421 requiredApproved · checked October 5, 2026
Write on scriptone applicable Reason for Use code, 130 or 412 or 421 (criteria below)
Ontario Limited Use criteria, code 130, 412, 421
Reason for Use code 130 To reduce the subjective symptoms and objective signs of cervical dystonia (spasmodic torticollis) in adults. Coverage limit: LU Authorization Period: 1 year Reason for Use code 412 For the management of focal spasticity, due to stroke or spinal cord injury in adults. Coverage limit: LU Authorization Period: 1 year Reason for Use code 421 For the treatment of blepharospasm associated with dystonia, including benign essential blepharospasm or VII nerve disorders in adults. Coverage limit: LU Authorization Period: 1 year Coverage limit: Xeomin should be administered personally by a neurologist or a physician with equivalent post-graduate training and experience with neuromuscular disorders.
No interchangeable product listed in the Ontario extract
Xeomin · DIN 02556227 Manufacturer: Merz Pharmaceutical Gmbh; listing date 2026-02-27 Health Canada: Approved since 2025-03-17 · brand XEOMIN · ATC M03AX01 BOTULINUM TOXIN · form Powder for solution · route Intramuscular, Intraglandular · ingredients INCOBOTULINUMTOXINA 200 UNIT/VIAL · company Merz pharmaceuticals gmbh · schedule Prescription, Schedule d
Re-check Health Canada status and shortages (live) · Health Canada product record

Xeomin: Formulary list price $677.82 per unit (the source does not state the unit; exact figure $677.8200). What the ministry pays, not the patient.

Ministry pays: $677.8200 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02556227)

Source record
DIN 02556227: Xeomin Raw flags: sec12=Y, sec3=Y Item: 920000805; group id 924; item number 2202; lccId 00427; manufacturer id MEZ Source form: Pd for Inj-Vial Pk (Preservative-Free); strength: 200 Units/Vial Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $677.8200; ministry $677.8200 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02556227 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104493
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02556227
Shortage record checked October 6, 2026
Health Canada lists this DIN as Approved since March 17, 2025 — choose a marketed DIN from the same-category list.

Other products in the same Health Canada class (M03AX): coverage varies; not interchangeable

  • Abobotulinum toxin a (Dysport Therapeutic): limited Use 130, 412, 413
  • Botulinum toxin type a (Botox): limited Use 130, 412, 413, 440, 460
Other drugs in the same formulary class (92:00 UNCLASSIFIED THERAPEUTIC AGENTS) and how they are covered

Matched class: 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ALENDRONATE & CHOLECALCIFEROL, AZATHIOPRINE, CYCLOSPORINE, GLUCAGON RDNA ORIGIN, LANREOTIDE ACETATE, LEFLUNOMIDE, LEVODOPA & BENSERAZIDE, MYCOPHENOLATE SODIUM, RISPERIDONE Some products covered without a code (check the product listing): ALENDRONATE, ALLOPURINOL, AMANTADINE HCL, BROMOCRIPTINE, CLOPIDOGREL BISULFATE, LEVODOPA & CARBIDOPA, MYCOPHENOLATE MOFETIL, OCTREOTIDE, RISEDRONATE SODIUM, ROPINIROLE, SELEGILINE HCL, TAMSULOSIN HCL 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

BOTULINUM TOXIN TYPE A

· 5 products · Limited Use, codes 10, 130, 412, 413, 440, 460 · strengths: 100U/Vial, 200U/Vial, 50U/Vial · Pd Inj-100U Vial Pk, Pd Inj-200U Vial Pk, Pd Inj-50U Vial Pk

ALENDRONATE

· 28 products · Off-Formulary Interchangeable, not an ODB benefit (4), Listed, not a benefit (1), General benefit (23) · strengths: 5mg, 10mg, 70mg · Tab

ALENDRONATE & CHOLECALCIFEROL

· 6 products · General benefit · strengths: 70mg & 70mcg, 70mg & 140mcg · Tab

ALLOPURINOL

· 10 products · General benefit (6), Listed, not a benefit (4) · strengths: 100mg, 200mg, 300mg · Tab

AMANTADINE HCL

· 5 products · Listed, not a benefit (2), General benefit (3) · strengths: 100mg, 10mg/mL · Cap, O/L

AZATHIOPRINE

· 3 products · General benefit · strengths: 50mg · Tab

BROMOCRIPTINE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 5mg, 2.5mg · Cap, Tab

CLOPIDOGREL BISULFATE

· 19 products · General benefit (16), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 75mg, 300mg · Tab

CYCLOSPORINE

· 8 products · General benefit · strengths: 10mg, 25mg, 50mg, 100mg, 100mg/mL · Cap, O/L

GLUCAGON RDNA ORIGIN

· 2 products · General benefit · strengths: 1mg/Vial · Inj Pd-Syr Pk, Inj Pd-Vial Pk

LANREOTIDE ACETATE

· 6 products · General benefit · strengths: 60mg/Syr, 90mg/Syr, 120mg/Syr · ER Pref Syr Pk

LEFLUNOMIDE

· 16 products · General benefit · strengths: 10mg, 20mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 92:00 and 78 more
Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS Xeomin (incobotulinumtoxinA) is indicated: • for the treatment of hypertonicity disorders of the 7th nerve such as blepharospasm including benign essential blepharospasm and hemifacial spasm in adults • to reduce the subjective symptoms and objective signs of cervical dystonia (spasmodic torticollis) in adults • for the treatment of spasticity of the upper limb in adults • for the treatment of post-stroke lower limb spasticity involving the ankle and foot in adults • for the treatment of chronic sialorrhea associated with neurological disorders in adults • for the treatment of chronic sialorrhea associated with neurological disorders in pediatric patients (age 2-17 years weighing 12 kg or more) Xeomin may only be used by physicians with suitable qualifications and experience in the application of Botulinum neurotoxin type A (BoNT/A) 1.1 Pediatrics Pediatrics (< 18 years of age): The safety and efficacy of Xeomin for the treatment of chronic (lasting at least 3 months) sialorrhea in children with neurological disorders below the age of 2 years or with a weight less than 12 kg, an… https://pdf.hres.ca/dpd_pm/00078891.PDF PM date: MAR 17, 2025 Source product: XEOMIN; DIN 02324032; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.